Literature DB >> 19601867

Esterase activities in the blood, liver and intestine of several preclinical species and humans.

Loren M Berry1, Lance Wollenberg, Zhiyang Zhao.   

Abstract

Species and tissue differences in the activity of three major classes of esterases, carboxylesterase (CE), butyrylcholinesterase (BChE) and paraoxonase (PON), were studied. Substantial species differences in activity of these esterases were observed between the mouse, rat, dog monkey and human. Such species differences must be considered when using these preclinical species to optimize the pharmacokinetic properties of ester compounds intended for human use.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19601867     DOI： 10.2174/187231209788654081

Source DB:  PubMed          Journal:  Drug Metab Lett        ISSN： 1872-3128


  25 in total

1.  Physiologically Based Absorption Modeling to Design Extended-Release Clinical Products for an Ester Prodrug.

Authors:  Xuan Ding; Jeffrey S Day; David C Sperry
Journal:  AAPS J       Date:  2016-07-12       Impact factor: 4.009

2.  Pharmacokinetic evaluation of the anticancer prodrug simmitecan in different experimental animals.

Authors:  Zhe-yi Hu; Xiu-xue Li; Fei-fei Du; Jun-ling Yang; Wei Niu; Fang Xu; Feng-qing Wang; Chuan Li; Yan Sun
Journal:  Acta Pharmacol Sin       Date:  2013-09-23       Impact factor: 6.150

3.  Synthesis and Biological Evaluation of Paclitaxel and Camptothecin Prodrugs on the Basis of 2-Nitroimidazole.

Authors:  Chen Jin; Shuai Wen; Qiumeng Zhang; Qiwen Zhu; Jiahui Yu; Wei Lu
Journal:  ACS Med Chem Lett       Date:  2017-06-27       Impact factor: 4.345

4.  The development of highly potent inhibitors for porcupine.

Authors:  Xiaolei Wang; Jesung Moon; Michael E Dodge; Xinchao Pan; Lishu Zhang; Jordan M Hanson; Rubina Tuladhar; Zhiqiang Ma; Heping Shi; Noelle S Williams; James F Amatruda; Thomas J Carroll; Lawrence Lum; Chuo Chen
Journal:  J Med Chem       Date:  2013-03-19       Impact factor: 7.446

5.  In vitro metabolism of pyripyropene A and ACAT inhibitory activity of its metabolites.

Authors:  Daisuke Matsuda; Taichi Ohshiro; Masaki Ohtawa; Hiroyuki Yamazaki; Tohru Nagamitsu; Hiroshi Tomoda
Journal:  J Antibiot (Tokyo)       Date:  2014-07-09       Impact factor: 2.649

6.  Contributions of intestine and plasma to the presystemic bioconversion of vicagrel, an acetate of clopidogrel.

Authors:  Zhixia Qiu; Ning Li; Ling Song; Yang Lu; Jing Jing; Harendra S Parekha; Wenchao Gao; Fengjie Tian; Xin Wang; Shuangxia Ren; Xijing Chen
Journal:  Pharm Res       Date:  2013-09-14       Impact factor: 4.200

7.  Physiologically based kinetic modelling based prediction of in vivo rat and human acetylcholinesterase (AChE) inhibition upon exposure to diazinon.

Authors:  Shensheng Zhao; Sebastiaan Wesseling; Bert Spenkelink; Ivonne M C M Rietjens
Journal:  Arch Toxicol       Date:  2021-03-14       Impact factor: 5.153

8.  Metabolism and Interspecies Variation of IMMH-010, a Programmed Cell Death Ligand 1 Inhibitor Prodrug.

Authors:  Yuchen Wang; Xiao Liu; Xiaowen Zou; Shuting Wang; Lijun Luo; Yuke Liu; Kai Dong; Xiaoqing Yao; Yan Li; Xiaoguang Chen; Li Sheng
Journal:  Pharmaceutics       Date:  2021-04-21       Impact factor: 6.321

9.  Aryl N-[ω-(6-Fluoroindol-1-yl)alkyl]carbamates as Inhibitors of Fatty Acid Amide Hydrolase, Monoacylglycerol Lipase, and Butyrylcholinesterase: Structure-Activity Relationships and Hydrolytic Stability.

Authors:  Stefan Rudolph; Helmut Dahlhaus; Walburga Hanekamp; Christian Albers; Maximilian Barth; Giulia Michels; Denise Friedrich; Matthias Lehr
Journal:  ACS Omega       Date:  2021-05-14

10.  Creation of a long-acting rilpivirine prodrug nanoformulation.

Authors:  James R Hilaire; Aditya N Bade; Brady Sillman; Nagsen Gautam; Jonathan Herskovitz; Bhagya Laxmi Dyavar Shetty; Melinda S Wojtkiewicz; Adam Szlachetka; Benjamin G Lamberty; Sruthi Sravanam; Howard S Fox; Yazen Alnouti; Prasanta K Dash; JoEllyn M McMillan; Benson J Edagwa; Howard E Gendelman
Journal:  J Control Release       Date:  2019-09-03       Impact factor: 9.776
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.